Akaishi, Tetsuya http://orcid.org/0000-0001-6728-4966
Misu, Tatsuro
Fujihara, Kazuo
Takahashi, Toshiyuki
Takai, Yoshiki
Nishiyama, Shuhei
Kaneko, Kimihiko
Fujimori, Juichi
Ishii, Tadashi
Aoki, Masashi
Nakashima, Ichiro
Funding for this research was provided by:
Ministry of Health, Labour and Welfare (20FC1030)
Japan Society for the Promotion of Science London (20K07892)
Article History
Received: 28 October 2021
Revised: 19 November 2021
Accepted: 19 November 2021
First Online: 25 November 2021
Declarations
:
: T. Akaishi, T. Misu, T. Takahashi, Y. Takai, S. Nishiyama, K. Kaneko, J. Fujimori, T. Ishii, and M. Aoki report no disclosures. K. Fujihara received speaker honoraria and travel funding from Bayer, Biogen Japan, Eisai, Mitsubishi Tanabe, Novartis, Astellas, Takeda, Asahi Kasei Medical, Daiichi Sankyo, and Nihon Pharmaceutical, and received research support from Bayer, Biogen, Asahi Kasei Medical, The Chemo-Sero-Therapeutic Research Institute, Teva, Mitsubishi Tanabe Pharma, Teijin, Chugai, Ono, Nihon Pharmaceutical, and Genzyme. I. Nakashima received speaker honoraria, travel funding, and advisory fee from Biogen Japan, Novartis Pharma, Alexion Pharma, and Chugai Pharmaceutical and received research support from LSI Medience.
: This study was approved by the Institutional Review Board of the Tohoku University Graduate School of Medicine (approval number: 2012120). All processes in this study were performed in accordance with the latest version of the Declaration of Helsinki, as revised in 2013.